"The drugs assessed in the new review target beta-amyloid proteins, which form plaques that seem to accumulate in the brains of people with Alzheimer's. Early trials suggested they might slow or prevent the disease, but further research hasn't corroborated those results."
"Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients, said the review's lead author Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna in Italy."
"The review found that the drugs not only seem to have no beneficial effect but also increase the risk of brain bleeding and swelling."
A new Cochrane review indicates that drugs targeting beta-amyloid proteins, once considered breakthroughs for Alzheimer's treatment, do not significantly affect disease progression. The review analyzed 17 clinical trials and found that while early studies suggested potential benefits, subsequent research failed to support these claims. Additionally, the drugs pose risks, including increased chances of brain bleeding and swelling. The review's lead author, Francesco Nonino, emphasized that the evidence shows these drugs do not provide meaningful benefits to patients.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]